[Articles] Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Related Posts

• [Articles] Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

  Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however…

• [Articles] Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

  Adjuvant carboplatin and paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy for unselected locally advanced cervical…

• Concurrent and Adjuvant Durvalumab With Chemoradiotherapy in Advanced Cervical Cancer

  KEY TAKEAWAYS The phase III CALLA trial (NCT03830866) will evaluate the efficacy and safety of…